BioCentury
ARTICLE | Clinical News

MORAb-004: Additional Phase I data

June 4, 2012 7:00 AM UTC

Additional data from a dose-escalation, open-label, U.S. Phase I trial in 36 patients with refractory solid tumors showed that once-weekly 0.0625-16 mg/kg IV MORAb-004 produced 4 minor or mixed tumor responses, and 18 cases of stable disease, including 4 in patients with colorectal cancer. The MTD was 12 mg/kg MORAb-004, with 1 DLT of grade 3 vomiting at the 16 mg/kg dose. The most common adverse events included fever, chills, headache and myalgia. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...